Connect with us


Ramaphosa welcomes SA Biovac and Pfizer collaboration

Published on

The presidency has confirmed that President Ramaphosa welcomed a collaboration between SA’s Biovac Institute and Pfizer, to produce the Pfizer-BioNTech vaccine in Cape Town for distribution in Africa.

President Cyril Ramaphosa, on Wednesday, 21 July 2021, welcomed the announcement of a collaboration between South Africa’s Biovac Institute and the global pharmaceutical producer Pfizer, as a breakthrough in the protection of African nations against the COVID-19 virus. The presidency noted that as the African Union (AU) champion on COVID-19, the president stated, “Today’s agreement will contribute significantly to health security and sustainability on our continent, which currently has the least access to vaccination in the world.”

The presidency also confirmed that Biovac and Pfizer announced that the Pfizer vaccine will be produced in Cape Town by the Biovac Institute. Moreover, Biovac is a vaccine producer and public-private partnership between the South African Government and the pharmaceutical private sector.

The presidency further confirmed that Biovac will manufacture the Pfizer-BioNTech vaccine for distribution in Africa, making it the first company in Africa to produce an mRNA-based vaccine. According to the presidency, Biovac is said to immediately embark on technological transfer activities which include on-site development and equipment installation for production of the Pfizer vaccine, and expects the facility to be brought into the Pfizer supply chain by the end of 2021. Ramaphosa wished the partnership well.

See the post below.

Mahlohonolo Lakaje
[email protected]

Copyright © 2021 Political Analysis South Africa

error: Copyrighted Content